Sirtuin Signalling Peptides in Canada: A Research Guide to NAD+, SIRT1, SIRT3, Mitochondria, Epitalon, MOTS-c, SS-31, and RUO Sourcing

Why sirtuin signalling needed a separate anti-ageing guide#

Northern Compound already covers NAD+, MOTS-c, SS-31, cellular senescence, mitophagy, DNA repair, proteostasis, and epigenetic-clock peptide research. Those articles mention sirtuins because the pathway touches many ageing-biology topics. What was missing was a guide centred on sirtuin signalling itself: when should a Canadian reader accept a sirtuin claim, and when is it only a broad longevity label?

That gap matters because sirtuins are easy to turn into marketing shorthand. A product page may say that a compound "activates longevity genes." A paper may report a change in NAD+ or mitochondrial respiration. A forum summary may turn SIRT1 or SIRT3 into a generic anti-ageing switch. Those statements are not equivalent. Sirtuins are enzyme families with compartment-specific biology, substrate specificity, cofactor dependence, and model-dependent effects.

SIRT1 is usually discussed around nuclear and cytosolic regulation: transcription factors, DNA-damage response, inflammation, metabolism, circadian biology, and stress adaptation. SIRT3 is usually discussed around mitochondria: respiratory enzymes, antioxidant defence, fatty-acid oxidation, and mitochondrial stress. Other sirtuins—SIRT2, SIRT4, SIRT5, SIRT6, and SIRT7—also matter, but most peptide-adjacent anti-ageing content collapses the family into SIRT1 or SIRT3 language.

This article is written for Canadian readers evaluating research-use-only peptide literature, supplier pages, and assay design. It does not provide medical advice, disease-treatment guidance, cosmetic claims, human optimisation advice, dosing, route selection, compounding instructions, or personal-use recommendations.

The short answer: do not call it a sirtuin effect unless sirtuin biology was measured#

A defensible sirtuin project starts with a measurable claim. "Supports longevity" is not a method. "Raises NAD+" is useful but incomplete. "Increases SIRT1 activity and lowers acetylated p53 in irradiated fibroblasts while preserving viability" is a testable statement. "Improves mitochondrial respiration and decreases acetylated SOD2 in a SIRT3-dependent model" is stronger still.

Within the current Northern Compound product map, NAD+ is the most direct live product reference for sirtuin-adjacent research because sirtuins require NAD+ as a co-substrate. MOTS-c is relevant when AMPK, metabolic stress adaptation, mitonuclear signalling, and nutrient sensing may intersect with SIRT1 or SIRT3 readouts. SS-31 belongs when mitochondrial membrane stress, cardiolipin context, respiration, ROS, and SIRT3-adjacent mitochondrial acetylation are measured. Epitalon is an ageing-biology comparator when circadian, telomere, or epigenetic-clock endpoints are part of the panel, but it should not be treated as a direct sirtuin activator unless the study measures that layer.

A ProductLink is a route to inspect current research-use-only availability and documentation. It is not evidence of efficacy, safety, suitability, route, dosing, clinical value, or personal-use appropriateness.

Sirtuin biology in one cautious map#

Sirtuins are NAD+-dependent enzymes. Most are deacetylases, although several also remove other acyl modifications or perform ADP-ribosyltransferase-related chemistry. Their dependency on NAD+ is why they sit near redox state, energy balance, DNA repair, mitochondrial stress, inflammation, and ageing research. When NAD+ availability changes, sirtuin activity may change—but not automatically, not uniformly, and not always in the direction a marketing headline implies.

The family is compartmentalized. SIRT1 is commonly described as nuclear and cytosolic. SIRT2 is often cytosolic and cell-cycle or cytoskeleton-adjacent. SIRT3, SIRT4, and SIRT5 are mitochondrial. SIRT6 and SIRT7 are nuclear and linked to chromatin, genome stability, ribosomal biology, and stress responses. A study claiming "sirtuin activation" should therefore say which sirtuin, which compartment, which substrate, and which cell state.

Reviews of sirtuin biology emphasize that sirtuins integrate metabolism, chromatin, stress resistance, mitochondrial function, and ageing-related phenotypes rather than acting as one simple longevity lever (PubMed search: sirtuins aging review). NAD+ reviews likewise describe age-associated NAD+ changes through synthesis, consumption, PARP activity, CD38, mitochondrial function, and inflammatory context (PMC7963035). Those are research frameworks, not consumer promises.

For peptide-adjacent research, the practical lesson is to connect the product hypothesis to the enzyme layer. If the material is NAD+, measure NAD+ and downstream sirtuin substrates. If the material is mitochondrial, measure mitochondrial acetylation and SIRT3-adjacent endpoints. If the material is metabolic, measure AMPK, nutrient sensing, and sirtuin substrates. If the material is clock- or telomere-adjacent, show why sirtuins are actually part of the mechanism.

NAD+: the co-substrate, not the conclusion#

NAD+ is the most direct RUO reference in a sirtuin article because sirtuins consume NAD+ during deacylation reactions. But NAD+ is not synonymous with sirtuin activity. It is also used by PARP enzymes during DNA-damage response, by CD38 and other NADases, and by redox reactions throughout metabolism. A change in NAD+ can reflect synthesis, salvage, consumption, compartmental shifts, extraction artefacts, stress level, or cell viability.

A strong NAD+ sirtuin protocol therefore separates four questions:

1. Did NAD+ actually change? The protocol should specify the assay, extraction conditions, tissue or cell compartment, timing, and whether NADH or related metabolites were measured.
2. Did sirtuin activity change? SIRT1 or SIRT3 abundance alone is not enough. Substrate acetylation or activity assays are stronger.
3. Was the result specific? PARP activation, CD38 expression, cell death, proliferation, and mitochondrial mass can all change the interpretation.
4. Did the phenotype require sirtuins? Knockdown, inhibition, rescue, or substrate-level evidence can help avoid a correlation-only claim.

For SIRT1, common substrate readouts include acetylated p53, FOXO-family transcription factors, NF-kB p65, PGC-1 alpha, and circadian regulators. For SIRT3, common readouts include acetylated SOD2, enzymes involved in fatty-acid oxidation, tricarboxylic-acid-cycle regulation, and respiratory-chain function. The specific substrate should match the model.

Canadian readers should also distinguish chemical identity. An RUO NAD+ reference is not interchangeable with every precursor, supplement, derivative, topical formulation, intravenous clinic claim, or clinical protocol discussed online. In the Northern Compound context, the question is whether a research material is documented well enough for a defined non-clinical assay and whether the claim stays inside that evidence.

MOTS-c: metabolic stress may intersect with SIRT1, but it is not a sirtuin product#

MOTS-c is a mitochondrial-derived peptide discussed around metabolic stress response, AMPK activation, glucose-handling models, exercise-like signalling, mitonuclear communication, and cellular adaptation. Those mechanisms can intersect with sirtuin biology because AMPK, NAD+ salvage, mitochondrial demand, nutrient sensing, and SIRT1/PGC-1 alpha signalling are linked in many metabolic models.

The key word is intersect. MOTS-c should not be described as a direct sirtuin activator unless the study demonstrates that layer. A metabolic study can show AMPK phosphorylation, altered glucose handling, improved stress tolerance, or changed mitochondrial function without proving that SIRT1 or SIRT3 caused the effect. A stronger sirtuin-adjacent MOTS-c design would measure NAD+/NADH, SIRT1 activity or substrates, SIRT3 substrates if mitochondria are central, AMPK, PGC-1 alpha acetylation, mitochondrial respiration, ROS, viability, and time course.

This distinction is especially important in ageing content. MOTS-c may be relevant to age-associated metabolic stress models, but that does not make it a universal longevity intervention. The claim should name the model: aged tissue, metabolic challenge, cultured cells under stress, mitochondrial dysfunction, or nutrient-sensing pathway. It should then name the endpoint: AMPK, SIRT1, SIRT3, respiration, inflammatory tone, senescence marker, or tissue function.

For sourcing, MOTS-c documentation should include lot-specific identity, mass confirmation, HPLC purity, fill amount, batch traceability, storage conditions, and RUO labelling. Metabolic and mitochondrial assays are sensitive to concentration error, degradation, residual solvents, salts, and handling history. Without material control, a sirtuin signal can be an artefact.

SS-31: mitochondrial membrane stress and SIRT3-adjacent readouts#

SS-31, also known as elamipretide in clinical-development literature, is a mitochondria-targeted tetrapeptide discussed around cardiolipin, inner-membrane stress, oxidative damage, and bioenergetics. It is relevant to sirtuin research primarily through mitochondrial function and SIRT3-adjacent acetylation biology, not because it is a canonical sirtuin compound.

SIRT3 is a major mitochondrial deacetylase. It is often discussed around antioxidant defence, fatty-acid oxidation, electron-transport-chain proteins, and stress adaptation. If SS-31 improves mitochondrial respiration or lowers ROS in a model, a sirtuin-aware protocol can ask whether SIRT3 activity or substrate acetylation changed in parallel. But a respiratory improvement alone does not prove SIRT3 involvement. It may reflect membrane stabilisation, lower cardiolipin oxidation, altered substrate flux, preserved viability, or reduced upstream stress.

A strong SS-31 sirtuin-adjacent panel might include oxygen-consumption rate, ATP-linked respiration, mitochondrial membrane potential, ROS, cardiolipin oxidation, SIRT3 abundance, acetylated SOD2, acetylated mitochondrial enzyme targets, NAD+/NADH, mitochondrial mass, mitophagy markers, and viability controls. If the study claims SIRT3 dependence, genetic or pharmacological controls may be needed.

The commercial overreach to avoid is simple: mitochondrial does not mean sirtuin, and sirtuin does not mean anti-ageing benefit. SS-31 can be a coherent mitochondrial research reference while still requiring pathway-specific evidence before sirtuin language is used.

Epitalon: clock, telomere, and epigenetic context rather than direct sirtuin activation#

Epitalon appears in anti-ageing discussions because the literature and supplier ecosystem often connect it with telomere, pineal, circadian, and epigenetic themes. Those themes can sit near sirtuin biology because SIRT1 and SIRT6 intersect with chromatin, DNA repair, metabolism, and circadian regulation. But adjacency is not mechanism.

A careful Epitalon sirtuin hypothesis should explain the bridge. Is the model asking whether circadian gene expression changes SIRT1-linked metabolic timing? Is telomere-associated damage being paired with SIRT6 or DNA-repair endpoints? Is epigenetic-clock language being connected to chromatin deacetylation markers? If the answer is no, Epitalon belongs in a telomere, clock, or epigenetic-clock article rather than a sirtuin claim.

Useful endpoints might include clock genes, hTERT expression, telomere length or telomere-associated damage foci, DNA-damage markers, SIRT1 or SIRT6 abundance, relevant substrate acetylation, chromatin marks, and cell-state controls. The same compliance rule applies: these are non-clinical research concepts, not personal anti-ageing guidance.

Assay design: build a sirtuin panel, not a slogan#

Sirtuin studies are vulnerable to single-marker storytelling. A protocol measures NAD+ and declares SIRT1 activation. Another measures lower ROS and declares SIRT3 support. Another measures lower IL-6 and declares anti-ageing. Each result may be interesting; none is complete by itself.

A stronger sirtuin panel usually combines:

• Cofactor state: NAD+, NADH, NAD+/NADH ratio, and extraction timing.
• Enzyme layer: SIRT1, SIRT3, or other sirtuin abundance plus activity or substrate acetylation.
• Substrate layer: acetylated p53, FOXO, NF-kB p65, PGC-1 alpha, SOD2, IDH2, LCAD, or model-relevant substrates.
• Competing NAD+ demand: PARP activity, PARylation, DNA-damage markers, CD38 expression or activity, inflammatory state.
• Phenotype layer: mitochondrial respiration, ROS, ATP, DNA repair, SASP output, cell-cycle markers, stress survival, or tissue function.
• Material-quality layer: lot identity, purity, mass confirmation, fill amount, batch number, storage, test date, and RUO claims discipline.

Timing is central. NAD+ can change quickly. Sirtuin substrate acetylation may shift on a different timeline. DNA repair and PARP activation can consume NAD+ during stress. Mitochondrial respiration may improve before or after acetylation changes. Senescence or inflammatory phenotypes can require much longer windows. A single time point often cannot distinguish cause from compensation.

Model selection: the sirtuin family is tissue- and compartment-specific#

A sirtuin result in one model should not be treated as universal. SIRT1 in a hepatocyte nutrient-stress model is not the same as SIRT1 in a fibroblast DNA-damage model. SIRT3 in skeletal muscle mitochondria is not the same as SIRT3 in neurons, immune cells, adipocytes, or cultured transformed cell lines. SIRT6 chromatin biology is not interchangeable with SIRT1 or SIRT3.

Canadian readers should ask five model questions before trusting a claim:

1. Which sirtuin is being discussed? SIRT1, SIRT3, SIRT6, and other family members answer different questions.
2. Where is it measured? Nuclear, cytosolic, and mitochondrial compartments require different extraction and interpretation.
3. What substrate anchors the claim? Enzyme abundance without substrate evidence can be misleading.
4. What stressor or ageing model was used? Nutrient stress, oxidative injury, irradiation, replicative ageing, inflammation, and mitochondrial toxins are different states.
5. Does the material quality support subtle pathway work? Sirtuin assays can be sensitive to degradation, contamination, concentration error, and storage history.

The model should drive product selection. Use NAD+ when cofactor availability is the centre. Use MOTS-c when nutrient sensing and metabolic stress are central. Use SS-31 when mitochondrial membrane stress and SIRT3-adjacent endpoints are central. Use Epitalon only when clock, telomere, or epigenetic endpoints are explicit and the study actually measures a sirtuin bridge.

Negative controls and dependency tests#

The most persuasive sirtuin studies do not stop at correlation. They ask whether the proposed enzyme layer is necessary for the phenotype. That can be difficult, but even a modest dependency test improves interpretation.

For SIRT1-centred designs, dependency evidence may include SIRT1 knockdown, an appropriate inhibitor control, substrate-specific acetylation rescue, or a comparison with cells that cannot mount the same SIRT1 response. For SIRT3-centred designs, dependency evidence may include SIRT3-deficient models, mitochondrial-substrate acetylation controls, or rescue experiments that separate preserved mitochondrial mass from altered deacetylation. For NAD+-centred designs, the protocol may need PARP or CD38 context because a material can change NAD+ demand without directly engaging the sirtuin layer.

Negative controls are just as important. A heat-stressed or degraded material can produce cell stress that looks like pathway activation. A vehicle can change pH or osmolarity. A high concentration can reduce viability and artificially lower inflammatory output. A mitochondrial assay can look improved if only healthier cells survive. These are not trivial details. Sirtuin endpoints often sit downstream of general stress, so the study must show that the pathway is being regulated rather than merely responding to toxicity.

Useful control questions include:

• Does the result persist after normalising for cell number and viability?
• Are total protein levels and loading controls reported beside phospho or acetylation markers?
• Does a sirtuin substrate move in the expected direction before the phenotype changes?
• Are PARP activation, DNA damage, and NAD+ depletion measured when genotoxic stress is part of the model?
• Are mitochondrial mass and membrane potential separated from respiratory efficiency?
• Does the same lot perform consistently across replicate runs and storage intervals?

A supplier or article does not need every control for every claim. It does need controls that match the claim being made. The narrower the claim, the easier it is to support. The broader the claim—especially anti-ageing, longevity, rejuvenation, or systemic resilience—the stronger the control burden becomes.

Practical endpoint matrix for sirtuin-aware peptide research#

A practical Canadian RUO protocol can be built in tiers. The first tier verifies material and cofactor state. The second tier verifies the enzyme and substrate. The third tier asks whether the phenotype makes biological sense. The fourth tier tests dependency where feasible.

This tiered approach prevents product-category confusion. NAD+ may score high on Tier 1 while still needing substrate evidence for Tier 2. MOTS-c may score high on metabolic phenotype while still needing SIRT1 substrate evidence. SS-31 may score high on mitochondrial function while still needing SIRT3 dependency evidence. Epitalon may score high on clock or telomere context while needing a measured bridge before sirtuin language is justified.

Storage and handling variables that can masquerade as sirtuin biology#

Storage details can sound mundane compared with SIRT1, SIRT3, AMPK, PARP, or mitochondrial respiration, but they are part of the evidence. NAD+ and peptide materials can be affected by heat, light, moisture, repeated freeze-thaw exposure, pH, adsorption to plastics, oxidation, and time after reconstitution or solution preparation. This article does not provide preparation instructions. It simply notes that storage and handling history must be recorded when enzyme and mitochondrial endpoints are subtle.

For NAD+-centred work, exact chemical identity and degradation context matter because an assay may detect related metabolites or downstream effects rather than intact starting material. For mitochondrial peptides, oxidation, aggregation, salt form, residual solvent, and concentration error can alter cell stress. For Epitalon or MOTS-c, sequence identity and lot consistency matter because small peptides can be mislabelled or diluted while still producing a plausible-looking generic COA.

A strong lab record should capture supplier, lot, COA version, receipt date, storage temperature, thaw history where relevant, assay date, vehicle, concentration verification where possible, and any deviation from supplier storage guidance. That record is not marketing copy. It is the chain of evidence that makes a pathway claim interpretable.

COA-first sourcing for Canadian sirtuin research#

Sirtuin biology is often subtle. Small differences in material identity, concentration, pH, residual solvents, salts, oxidation, light exposure, storage temperature, or repeated freeze-thaw history can change cell stress and enzyme readouts. That makes supplier review part of the method rather than a purchasing afterthought.

A credible RUO review should ask for:

1. Lot-specific identity confirmation. Mass spectrometry or comparable evidence should match the labelled material.
2. Purity method and result. HPLC or another appropriate method should be lot-specific rather than a generic certificate reused across batches.
3. Fill amount and batch traceability. The vial, COA, order, and label should connect to the same lot.
4. Storage and test date. NAD+ and peptide materials can be sensitive to heat, light, moisture, oxidation, and handling.
5. Sequence, molecular weight, salt, counterion, or complex context. Exact identity matters when assays are sensitive.
6. Contamination awareness. Endotoxin or microbial context can distort inflammatory and senescence endpoints.
7. Claims discipline. The supplier should maintain research-use-only language and avoid dosing, injection, anti-ageing treatment, disease, cosmetic transformation, or personal-use claims.

For live documentation checks, readers can inspect NAD+, MOTS-c, SS-31, and Epitalon. These links preserve Northern Compound attribution. They are not endorsements of personal use and do not replace independent lot-level review.

Health Canada has warned consumers about unauthorized peptide products promoted online, especially where products are positioned for injection or personal therapeutic use (Health Canada, 2024). A research article can discuss sirtuin biology without turning RUO materials into consumer products.

How this guide fits with the anti-ageing archive#

Use NAD+ in Canada when the question is compound-level background, redox chemistry, and sourcing. Use mitophagy peptides when the endpoint is selective mitochondrial quality control. Use cellular senescence peptides when the question is durable growth arrest, SASP, p16, p21, and senomorphic versus senolytic interpretation. Use DNA repair peptides when PARP demand, gamma-H2AX, repair kinetics, and genome maintenance are central. Use epigenetic-clock peptide research when methylation clocks and chromatin-ageing claims are the topic.

This sirtuin guide sits between those pages. It is the pathway layer that asks whether an NAD+-dependent enzyme family actually explains the observation. The answer may be yes, but only if the study measures the cofactor, the enzyme, the substrate, the competing NAD+ demand, the phenotype, and the material quality.

Red flags in sirtuin and longevity marketing#

Be cautious when a page:

• says "activates longevity genes" without naming SIRT1, SIRT3, SIRT6, or a measured substrate;
• treats NAD+ level as proof of sirtuin activation;
• treats any mitochondrial improvement as a SIRT3 result;
• treats lower inflammation as senescence reversal;
• combines NAD+, MOTS-c, SS-31, and Epitalon into a generic anti-ageing stack without endpoint-specific hypotheses;
• cites clinical ageing or supplement literature as if it validates an RUO peptide lot;
• lacks lot-specific HPLC, mass confirmation, fill amount, batch number, storage conditions, or RUO labelling;
• provides dosing, cycling, injection, cosmetic, therapeutic, disease, or personal-use claims.

The better interpretation is narrower: a material may be relevant to a sirtuin hypothesis if the model and endpoints justify that claim. It does not become a longevity intervention because a pathway name appears in a paper.

Reference themes worth checking#

Readers auditing the literature should start with review-level maps, then move to model-specific primary papers. Useful entry points include sirtuins aging review, SIRT1 NAD metabolism review, SIRT3 mitochondrial deacetylase review, NAD aging CD38 PARP sirtuins review, and MOTS-c AMPK sirtuin research. These searches are starting points for checking model fit. They are not endorsements of personal use.

The best reading habit is to ask: what material was tested, what model was used, which sirtuin was measured, which substrate moved, what competing NAD+ demands were controlled, and whether the supplier product being evaluated has independent lot documentation.

Frequently asked questions#

Bottom line#

Sirtuin signalling is a useful anti-ageing research frame because it connects NAD+ availability, enzyme activity, substrate acetylation, DNA repair, mitochondrial function, metabolism, inflammation, and senescence biology. It is also easy to misuse. A serious claim should identify the sirtuin, the compartment, the substrate, the cofactor state, the phenotype, and the material-quality controls.

For Canadian RUO evaluation, NAD+ is the most direct live product reference for cofactor-centred sirtuin work. MOTS-c can support nutrient-sensing hypotheses when SIRT1-adjacent endpoints are measured. SS-31 can support mitochondrial-stress hypotheses when SIRT3-adjacent endpoints are measured. Epitalon belongs only when clock, telomere, or chromatin questions include a real sirtuin bridge. None should be presented as a personal anti-ageing intervention, treatment option, dosing protocol, or medical recommendation.